Market Newsdesk

SHANGHAI, Nov. 30, 2020 /PRNewswire/ — Quectel Wireless Solutions today announced the integration of the Qualcomm® 212 LTE IoT Modem from Qualcomm Technologies, Inc. into Quectel’s BC660K-GL high-performance LTE Cat NB2 narrowband IoT (NB-IoT) module. The module, which is pending certification with leading global carriers, offers extremely low-power consumption and supports multiple frequency bands.

Quectel’s module has an ultra-compact profile of 17.7 mm × 15.8 mm × 2.0 mm and, because the module is designed to be compatible with Quectel’s GSM/GPRS M66 module and NB-IoT BC66 module, it provides a flexible and scalable platform for migrating from GSM/GPRS to NB-IoT networks.

With NB-IoT networks rolling out globally, a growing number of IoT applications are selecting the technology. Quectel has therefore developed the BC660K-GL module to address the needs of chipset manufacturers for large-scale manufacturing with strict cost and efficiency requirements.

“We’re delighted that the Qualcomm 212 LTE IoT Modem is being integrated into our BC660K-GL module,” said Neset Yalcinkaya, VP of Products at Quectel Wireless Solutions. “This versatile module provides excellent performance with low power consumption. Our teams are collaborating with Qualcomm Technologies to ensure the modules are certified by global carriers and we look forward to bringing commercial products to market early in 2021.”

“Integrating the Qualcomm 212 LTE IoT Modem into Quectel’s NB-IoT module will help enable the creation of new, global smart IoT devices and applications,” said Vieri Vanghi, vice president, product management, Qualcomm Europe, Inc. “Together with Quectel, we are better able to meet global manufacturers’ demands for low-power, ultra-compact and cost-efficient IoT technologies.”

Engineering samples of the BC660K-GL NB-IoT module are available now.

Please visit the Quectel website: https://www.quectel.com/infocenter/news/quectel-selects-qualcomm-212-lte-iot-modem-for-integration-into-bc660k-gl-module.htm 

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we create superior cellular and GNSS modules backed by outstanding support and services. Our growing global team of 2200 professionals, the largest in the IoT modules industry worldwide, ensures we are first to market and continue to set the pace of development. Listed on the Shanghai Stock Exchange (603236.SS), our international leadership is devoted to advancing IoT across the globe.

www.quectel.com

, LinkedIn, Facebook and Twitter.

Contact: Ashley Liu, 86-551-6586-9386 x 8016,

[email protected]

Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.

Qualcomm 212 LTE IoT Modem is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.

View original content:http://www.prnewswire.com/news-releases/quectel-selects-qualcomm-212-lte-iot-modem-for-integration-into-bc660k-gl-module-301181553.html

SOURCE Quectel

BEIJING, Nov. 30, 2020 /PRNewswire/ — Fang Holdings Limited (NYSE: SFUN) (“Fang” or the “Company”), a leading real estate Internet portal in China, today announced that its board of directors (the “Board”) has received a preliminary and non-binding proposal letter, dated November 30, 2020, from General Atlantic Singapore Fund Pte. Ltd. (together with its affiliated investment entities, “General Atlantic”, as the “Proposing Buyer”), a company incorporated in Singapore, proposing to acquire all of the outstanding shares (the “Shares”) and American Depositary Shares (the “ADSs”, each representing ten Class ordinary shares) of the Company not currently owned by the Proposing Buyer in a “going-private” transaction for US$1.468 per Share (or US$14.68 per ADS) in cash, subject to certain conditions. The US$1.468 per Share (or US$14.68 per ADS) price represents a premium of approximately 20% to the closing price of the Company’s ADS on November 27, 2020, and a premium of approximately 40% to the Company’s 30-day volume weighted average price of ADS up to November 27, 2020. 

According to the proposal letter, the Proposing Buyer plans to finance the acquisition primarily with equity capital, and possibly debt capital. The proposal letter states that the equity portion of the financing would be provided by the Proposing Buyer and additional potential buyer consortium members, if any. A copy of the proposal letter is attached hereto as Annex A.

The Board cautions the Company’s shareholders and others considering trading the Company’s securities that the Board has just received the proposal letter and has not had an opportunity to carefully review and evaluate the proposal or make any decision with respect to the Company’s response to the proposal. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to this or any other transaction, except as required under applicable law.

About Fang

Fang operates a leading real estate Internet portal in China in terms of the number of page views and visitors to its websites. Through its websites, Fang provides primarily marketing, listing, leads generation and financial services for China’s fast-growing real estate and home furnishing and improvement sectors. Its user-friendly websites support active online communities and networks of users seeking information on, and value-added services for, the real estate and home furnishing and improvement sectors in China. Fang currently maintains approximately 74 offices to focus on local market needs and its website and database contains real estate related content covering 665 cities in China. For more information about Fang, please visit http://ir.fang.com.

Safe Harbor Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the approval and the consummation of the potential transaction contemplated by the proposal letter or any alternative transaction. These forward-looking statements can be identified by terminology such as “will,” “expects,” “is expected to,” “anticipates,” “aim,” “future,” “intends,” “plans,” “believes,” “are likely to,” “estimates,” “may,” “should” and similar expressions, and include, without limitation, statements regarding Fang’s future financial performance, revenue guidance, growth and growth rates, market position and continued business transformation. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Fang’s control, which may cause its actual results, performance or achievements to differ materially from those in the forward-looking statements. Potential risks and uncertainties include, without limitation, the impact of Fang’s business development strategies, the impact of the COVID-19 pandemic, and the impact of current and future government policies affecting China’s real estate market. Further information regarding these and other risks, uncertainties or factors is included in Fang’s filings with the U.S. Securities and Exchange Commission. Fang does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Annex A

November 30, 2020

The Board of Directors
Fang Holdings Limited
Tower A, No. 20 Guogongzhuang Middle Street
Fengtai District, Beijing 100070
The People’s Republic of China

Dear Board Members:

General Atlantic Singapore Fund Pte. Ltd. (together with its affiliated investment entities, “General Atlantic”, as the “Proposing Buyer”) hereby submits this preliminary non-binding proposal (the “Proposal”) to acquire all of the outstanding shares and American Depositary Shares (“ADSs”, each representing ten Class A ordinary shares), of Fang Holdings Limited (the “Company”), not already beneficially owned by General Atlantic (the proposed “Transaction”).

We believe that our Proposal provides an attractive opportunity for the Company’s shareholders, especially during a time of persisting operating difficulty and ongoing COVID-19 uncertainty. The Proposal represents a premium of 20% to the Company’s stock price as of the close of business on November 27, 2020 and a premium of approximately 40% to the Company’s 30-day volume weighted average price up to November 27, 2020.

Set forth below are the primary terms of our Proposal:

1.  Purchase Price. We propose to acquire all of the outstanding ordinary shares and ADSs of the Company not already beneficially owned by General Atlantic. The consideration payable for each ADS to be acquired will be US$14.68 in cash, and the consideration payable for each ordinary share to be acquired will be US$1.468 in cash.

2.  Funding. We intend to finance the Transaction primarily with equity capital, and possibly debt capital. Equity financing will be provided from us as the Proposing Buyer and additional potential buyer consortium members, if any.

3.  Due Diligence. We believe that we will be in a position to complete customary due diligence for the Transaction in a timely manner and in parallel with discussions of corresponding definitive agreements.

4.  Definitive Agreements. We are prepared to promptly negotiate and finalize definitive agreements (“Definitive Agreements”) for the Transaction. These documents will provide for representations, warranties, covenants and conditions which are typical, customary and appropriate for transactions of this type.

5.  Process. We believe that the Transaction will provide superior value to the Company’s shareholders. We recognize that the Company’s Board of Directors will likely need to evaluate the Transaction independently before the Company can make any determinations.

6.  About General Atlantic. General Atlantic is a leading global growth equity firm providing capital and strategic support for growth companies. Established in 1980, General Atlantic has more than 180 investment professionals based in New York, Greenwich, Palo Alto, São Paulo, London, Munich, Mexico City, Beijing, Shanghai, Hong Kong, Mumbai, Amsterdam, Singapore and Jakarta. General Atlantic combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with management teams to build exceptional businesses worldwide. General Atlantic has approximately $40 billion in assets under management, and the firm’s unique capital base is comprised of long-term commitments primarily from wealthy families and large charitable foundations; this affords General Atlantic with flexibility in investment structures and time horizon, enabling a strong partnership approach with growth companies.

7.  No Binding Commitment. This letter constitutes only a preliminary indication of our interest, and does not constitute any binding commitment with respect to the Transaction. A binding commitment will result only from the execution of Definitive Agreements, and then will be on terms and conditions provided in such documentation.

We would like to express our commitment to working collaboratively with the Company to bring this Transaction to a successful and timely conclusion. Should you have any questions regarding this proposal, please do not hesitate to contact us.

* * * * *

[Signature Page to Follow]

Sincerely,

General Atlantic Singapore Fund Pte. Ltd.

By:       /s/ Ong Yu Huat 
Name:  Ong Yu Huat
Title:    Director

View original content:http://www.prnewswire.com/news-releases/fang-holdings-limited-announces-receipt-of-non-binding-going-private-proposal-301181552.html

SOURCE Fang Holdings Limited

SHENZHEN, China, Nov. 30, 2020 /PRNewswire/ — ATIF Holdings Limited (Nasdaq: ATIF, the “Company”), a company providing business consulting and multimedia services in Asia and North America, today announced that through its viable interest entity, Qianhai Asia Times (Shenzhen) International Finance Services Co. Ltd., recently it signed a Strategic Cooperation Agreement with Shenzhen Huiju Innovation Park Operation Co., Ltd (“Huiju Innovation Park”), to target the technology-based enterprises as potential clients for the Company, for its financial consulting and overseas listing advisory services.

Based on the strategic cooperation, Huiju Innovation Park will be responsible for organizing financial forums, salons and exchange activities for the resident companies of Huiju Xinqiao 107 Innovation Park (“107 Innovation Park”), which is operated by Huiju Innovation Park, to connect with ATIF. ATIF will provide its professional services such as investment and financing consulting, connection of investment institutions and overseas listing advisory to the potential clients in 107 Innovation Park.

Mr. Pishan Chi, CEO of the Company commented, “We look forward to cooperating with Huiju Innovation Park and to serving technology-based enterprises. 107 Innovation Park is one of the 73 municipal business incubation bases recognized by the Shenzhen Municipal Government, with more than 50% of technology-based enterprises settled in the park. 107 Innovation Park’s mission is to help quality companies grow quickly and sustainably, which is in line with our service philosophy. Therefore, we are confident that we will be able to assist more emerging technology-based enterprises in Shenzhen to obtain overseas listing and/or financing.”

About Shenzhen Huiju Innovation Park Operation Co., Ltd

Huiju Xinqiao 107 Innovation Park (“107 Innovation Park”) is operated by Shenzhen Convergent Innovation Park Operation Co., Ltd. since 2017 and is located in Xinqiao Street, Bao’an District, Shenzhen, the hub of Guangdong-Hong Kong-Macao Greater Bay Area and the core area of the “Wisdom City” plan. 107 Innovation Park provides comprehensive services in finance, policies, regulations, taxation, industry standards, advertising, etc. In 2018, 107 Innovation Park has been recognized as “Shenzhen Science and Technology Enterprise Incubator”, “Shenzhen Key Park for Investment Promotion”, “Bao’an District Science and Technology Peach Blossom Garden”, “Bao’an Sino-German Cooperation Industrial Demonstration Park”, “Mobile FinSupermarket Service Point” and “South China Outstanding Park”.

About ATIF Holdings Limited

Headquartered in Shenzhen, China, ATIF Holdings Limited (“ATIF”) is a company providing business consulting services to small and medium-sized enterprises in Asia  and North America, including going public consulting services, international business planning and consulting services, and financial media services. ATIF operates an internet-based financial consulting service platform IPOEX.com, which provides prestige membership services including online capital market information, pre-IPO education and matchmaking services between SMEs and financing institutions. ATIF has advised several enterprises in China in their plans to become publicly listed in the U.S. Through its majority-owned subsidiary, Leaping Group Co., Ltd., ATIF also provides multimedia services and is engaged in three major businesses, including multi-channel advertising, event planning and execution, film and TV program production and movie theater operations. ATIF operates the largest pre-movie advertising network in Heilongjiang Province and Liaoning Province of China and also provides advertising services in elevators and supermarkets. ATIF is often hired to plan both online and offline advertising campaigns and to produce related advertising material. In addition, ATIF invests in films and TV programs and distributes them in movie theaters or through online platforms. ATIF is also one of majority shareholders of AeroCentury Corp. (NYSE American: ACY) which is an independent global aircraft operating lessor and finance company specializing in leasing regional jet and turboprop aircraft and related engines to airlines and commercial users worldwide. For more information, please visit https://ir.atifchina.com/.

Forward-Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantee of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, are: future financial and operating results, including revenues, income, expenditures, cash balances and other financial items; ability to manage growth and expansion; current and future economic and political conditions; ability to compete in an industry with low barriers to entry; ability to continue to operate through our VIE structure; ability to obtain additional financing in the future to fund capital expenditures; ability to attract new clients and further enhance brand recognition; ability to hire and retain qualified management personnel and key employees; trends and competition in the financial consulting services industry; a pandemic or epidemic; and other factors listed in the Company’s annual report on Form 20-F and other documents filed with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions you that actual results may differ materially from the anticipated results expressed or implied by the forward-looking statements we make. You should not rely upon forward-looking statements as predictions of future events. Forward-looking statements represent our management’s beliefs and assumptions only as of the date such statements are made. These forward-looking statements are made as of the date of this news release.

View original content:http://www.prnewswire.com/news-releases/atif-holdings-limited-enters-into-strategic-cooperation-with-shenzhen-huiju-innovation-park-operation-co-ltd-301181449.html

SOURCE ATIF Holdings Limited

EMERYVILLE, Calif., Nov. 30, 2020 /PRNewswire/ — Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, announced today record sales revenue from its consumer brands during this year’s Black Friday sales event.

Black Friday Biossance Online Business Highlights

• 3X sales revenue compared to 2019 Black Friday
• Biossance.com exceeded $1 million in sales revenue
• Number of customers increased 129% versus 2019
• 57% of first-time customers drove 60% of sales
• Average Black Friday order value was up 19% versus last year

Amyris’ consumer brands are experiencing an excellent fourth quarter with Biossance^TM, its Clean Beauty skincare brand, leading the way. The Biossance^TM brand recorded three times sales revenue compared to its 2019 Black Friday event.

Amyris also wholly owns Pipette^TM, its baby and mother care brand, and Purecane^TM, the purest, no-calorie sweetener. Each of the brands is available through its own direct-to-consumer online channel as well as through online and brick-and-mortar retail partners. Both brands experienced strong online consumer traffic during this year’s Black Friday event with over 50% of sales revenue originating from new customers.

Throughout 2020, consumers have shifted a significant part of their shopping to online, and this pattern continues into the holiday season with strong sales being generated from Amyris’ direct-to-consumer ecommerce sites; Biossance.com, Pipettebaby.com, and Purecane.com.

John Melo, President and Chief Executive Officer of Amyris commented, “Our Biossance.com business alone exceeded $1 million in sales revenue during the three-day Black Friday period. All our consumer brands and channels demonstrated a very strong performance on Black Friday, setting new company records for orders shipped and new consumers coming to our brands. We are on track to deliver as much sales revenue for our consumer business in the fourth quarter as we did for the entirety of 2019.”

Amyris invested in its digital readiness over the past few years to ensure easy access by consumers to its brands. In anticipation of consumers’ doing more online shopping this holiday season, extensive planning went into preparing the supply chain so that fulfillment and shipping would be able to respond to high consumer demand.

About Amyris
Amyris (Nasdaq: AMRS) is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 3,000 products from the world’s top brands, reaching more than 200 million consumers. Amyris is proud to own three consumer brands – all built around its No Compromise® promise of clean ingredients: Biossance™ clean beauty skincare, Pipette™ clean baby skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane. For more information, please visit www.amyris.com.

Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as the expected delivery of 2020 fourth quarter sales revenue for the Consumer business. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris’s liquidity and ability to fund operating and capital expenses, risks related to potential delays or failures in development, production and commercialization of products, risks related to Amyris’s reliance on third parties (including in the supply chain), and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo, No Compromise, Biossance, Pipette, and Purecane are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/amyris-delivers-record-black-friday-sales-301181432.html

SOURCE Amyris, Inc.

PHOENIX, Nov. 30, 2020 /PRNewswire/ — Nikola Corporation (NASDAQ: NKLA) today announced the signing of a non-binding Memorandum of Understanding (“MOU”) with General Motors for a global supply agreement related to the integration of GM’s Hydrotec fuel-cell system into Nikola’s commercial semi-trucks. This supersedes and replaces the transaction announced on September 8, 2020.

Under the terms of the MOU, Nikola and GM will work together to integrate GM’s Hydrotec fuel-cell technology into Nikola’s Class 7 and Class 8 zero-emission semi-trucks for the medium- and long-haul trucking sectors. As previously announced, Nikola expects to begin testing production-engineered prototypes of its hydrogen fuel-cell powered trucks by the end of 2021, with testing for the beta prototypes expected to begin in the first half of 2022. In addition, Nikola and GM will discuss the potential for the utilization of GM’s versatile Ultium battery system in Nikola’s Class 7 and Class 8 vehicles.

“We are excited to take this important step with GM, which provides an opportunity to leverage the resources, strengths and talent of both companies,” said Mark Russell, Chief Executive Officer of Nikola. “Heavy trucks remain our core business and we are 100% focused on hitting our development milestones to bring clean hydrogen and battery-electric commercial trucks to market. We believe fuel-cells will become increasingly important to the semi-truck market, as they are more efficient than gas or diesel and are lightweight compared to batteries for long hauls. By working with GM, we are reinforcing our companies’ shared commitment to a zero-emission future.”

The agreement between Nikola and GM is subject to negotiation and execution of definitive documentation acceptable to both parties. The MOU does not include the previously contemplated GM equity stake in Nikola or development of the Nikola Badger. As previously announced, the Nikola Badger program was dependent on an OEM partnership. Nikola will refund all previously submitted order deposits for the Nikola Badger.

About Nikola Corporation

Nikola Corporation is globally transforming the transportation industry. As a designer and manufacturer of zero-emission battery-electric and hydrogen-electric vehicles, electric vehicle drivetrains, vehicle components, energy storage systems, and hydrogen station infrastructure, Nikola is driven to revolutionize the economic and environmental impact of commerce as we know it today. Founded in 2015, Nikola Corporation is headquartered in Phoenix, Arizona. For more information, visit www.nikolamotor.com or Twitter @nikolamotor.

Forward Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Nikola’s expectations regarding the terms and potential benefits of the MOU or a definitive agreement with GM; Nikola’s expectations and timeline with respect to prototype and production and testing; the benefits of fuel-cell technology; and Nikola’s beliefs with respect to the benefits of its zero-emissions vehicles. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Nikola’s management and are not predictions of actual performance. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements, including but not limited to, the ability of Nikola and GM to enter into definitive documentation for a supply agreement and the terms of any such definitive documentation; the failure to realize the anticipated benefits of the MOU or any definitive agreement; general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; the potential effects of COVID-19; the impact of judicial, regulatory or administrative proceedings to which Nikola is, or may become a party; risks related to the rollout of Nikola’s business and the timing of expected business milestones; the effects of competition on Nikola’s future business; the availability of capital; and the other risks discussed under the heading “Risk Factors” in Nikola’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and other reports and documents Nikola’s files from time to time with the SEC. If any of these risks materialize or its assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. These forward-looking statements speak only as of the date hereof and Nikola specifically disclaims any obligation to update these forward-looking statements.

Media Contacts:

Nicole Rose

[email protected]
602-499-4795

Colleen Robar

[email protected]
313-207-5960

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nikola-signs-mou-with-general-motors-301181397.html

SOURCE Nikola Corporation

BEIJING, Nov. 30, 2020 /PRNewswire/ — Luokung Technology Corp. (NASDAQ: LKCO) (“Luokung” or the “Company”), one of the global leading spatial-temporal big-data processing technology companies, a leading interactive location-based services company in China, today announced that it won bid for Heilongjiang Institute of Technology (“HIT”) Smart Campus first phase procurement project of USD 1.3 million, which is expected to be completed by the end of this year. The second and third phases will be implemented based on the infrastructure built by the first phase. The amount for the second phase is approximately USD 8 million. As the exclusive service provider for the first phase, it is highly probable that the Company will continue to implement the subsequent phases.

The Company will build a comprehensive digital base for campus smart management and smart educational administration management that integrates software and hardware, all generated data is managed by the “Luokung SuperEngine Spatiotemporal Data Engine”. The first phase of the smart campus is a system based on the Internet of Things to integrate cloud desktop system, student sign-in system, faculty and student safety prevention and control system, emergency one-button alert system, environmental monitoring system, high-precision public area pandemic prevention and detection system, and other related smart systems. The construction of subsequent second and third phases of the project will rely on the digital base.

About Luokung Technology Corp.

Luokung Technology Corp. is one of the global leading spatial-temporal big-data processing technology companies and a leading interactive location-based services company in China. It provides integrated DaaS, SaaS, and PaaS services for Internet and Internet of Things of Spatial-Temporal big data based on its patented technology. Based on geographic information systems and intelligent Spatial-Temporal big data, it establishes city-level and industry-level digital twin holographic data models to actively serve smart cities, intelligent transportation, smart industry, LBS. http://www.luokung.com

Business Risks and Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook” and similar statements. Such statements are based upon management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

View original content:http://www.prnewswire.com/news-releases/luokung-won-bid-for-heilongjiang-institute-of-technology-smart-campus-project-expanding-the-iot-smart-campus-market-301181513.html

SOURCE Luokung Technology Corp.

LEHI, Utah, Nov. 30, 2020 /PRNewswire/ — Purple Innovation, Inc. (NASDAQ: PRPL) (“the Company”), the leader in comfort innovation and the creator of the renowned Purple® Mattress, announced today that the Board of Directors appointed Dawn Zier to the board and Paul Zepf was elevated to Chairman at its board meeting held on November 24, 2020. Both appointments filled vacated positions created by the retirement of Terry and Tony Pearce in August 2020.

“We are excited about the addition of Dawn Zier to Purple’s Board of Directors as the Company seeks to continue its accelerated growth trajectory in 2021 and beyond,” said Lead Independent Director Gary DiCamillo.

Purple Innovation CEO Joe Megibow added: “Dawn’s demonstrated experience in digital marketing and business transformation will be a valuable asset as Purple continues to take market share in the direct to consumer sleep market. Further, as Purple broadens its horizons in international and new comfort technology markets, she will add strong relevant insights into new growth markets and categories.”

Dawn Zier is the principal of Aurora Business Consulting, LLC and advises companies on business transformation, digital marketing and high-performance teams. Ms. Zier served as President and CEO of Nutrisystem, a leading provider of health improvement and weight loss solutions, from 2012 until March of 2019, when it was sold to Tivity Health. She assisted in the transition to Tivity as President/COO and Board Member until December 2019. Previously, Ms. Zier served in a variety of positions at Readers Digest Association, including President of International, President of Europe and President of Global Marketing. She currently serves on the board of directors of Hain Celestial Group, Spirit Airlines and Prestige Consumer Healthcare. Ms. Zier holds an MS in Electrical Engineering and Computer Science, as well as an MBA from the Massachusetts Institute of Technology (MIT).

Paul Zepf has been a director of Purple Innovation since August 2020 and previously acted as an advisor to the Company and a Board observer. Mr. Zepf previously was CEO of Global Partner Acquisition Corp., the predecessor to the Company, from its formation in June 2015 until February 2018. Previously Mr. Zepf was Managing Director and Head of Strategic Initiatives at Golub Capital (February 2014 to June 2015) and was Managing Principal of Corporate Partners II, a Lazard sponsored private equity fund from March 2005 until February 2014. Mr. Zepf has been a board member of Ironshore Ltd., a property casualty insurance company, and has served as a director of BIH Holdings. He has a BA, with highest honors, from the University of Notre Dame.

About Purple

Purple is a digitally-native vertical brand with a mission to help people feel and live better through innovative comfort solutions. We design and manufacture a variety of innovative, premium, branded comfort products, including mattresses, pillows, cushions, frames, sheets and more. Our products are the result of over 25 years of innovation and investment in proprietary and patented comfort technologies and the development of our own manufacturing processes. Our proprietary gel technology, Hyper-Elastic Polymer®, underpins many of our comfort products and provides a range of benefits that differentiate our offerings from other competitors’ products. We market and sell our products through our direct-to-consumer online channels, traditional retail partners, third-party online retailers and our owned retail showrooms. For more information on Purple, visit purple.com.

Investor Contact:

Brendon Frey, ICR
[email protected] 
203-682-8200

Purple Innovation, Inc.

Misty Bond

Director of Purple Communications
[email protected] 
385-498-1851

View original content to download multimedia:http://www.prnewswire.com/news-releases/purple-innovation-announces-board-appointments-301181370.html

SOURCE Purple Innovation, Inc.

WALTHAM, Mass., Nov. 30, 2020 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the Evercore ISI HealthCONx Conference on Tuesday, December 1, 2020, at 1:00 p.m. (EST).  Among other topics, Mr. Casper will provide the company’s current perspective on the impact of the COVID-19 pandemic and expectations for future financial performance.

You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com.

About Thermo Fisher Scientific 

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

Media Contact Information:
Ron O’Brien
Phone: 781-622-1242
E-mail: [email protected] 
Website: www.thermofisher.com

Investor Contact Information:
Ken Apicerno
Phone: 781-622-1294
E-mail: [email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-to-present-at-the-evercore-isi-healthconx-conference-on-december-1-2020-301181393.html

SOURCE Thermo Fisher Scientific

SOUTH PLAINFIELD, N.J., Nov. 30, 2020 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the registration-directed Phase 3 MOVE-FA study evaluating vatiquinone (PTC743) in children and young adults with Friedreich ataxia (FA). FA is a genetic, progressive, neurodegenerative movement disorder, typically diagnosed in childhood or adolescence.¹ PTC estimates that there are 25,000 patients with FA worldwide and there are currently no approved disease modifying therapies for FA. In a previous Phase 2 trial, vatiquinone demonstrated a statistically significant effect on disease severity at 24 months relative to age and stage-matched natural history controls as assessed by the validated Friedreich ataxia rating scale (FARS) score and a favorable safety profile. Vatiquinone has been granted Orphan Drug Designation and Fast Track Designation for Friedreich ataxia by the U.S. Food and Drug Administration (FDA).

“The initiation of another pivotal trial this year is a major milestone for PTC,” said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. “This is the third clinical trial initiated this year based on compounds using our Bio-e platform. Vatiquinone is an exciting orally bioavailable small molecule that targets 15-lipoxygenase, the key enzyme regulating signaling pathways that control neuroinflammation and oxidative stress. Both pathways are important players in determining the pathology and disease progression seen in Friedreich ataxia patients. Previous clinical trial results give us confidence in vatiquinone’s potential in treating patients living with this devastating disease.”

The Phase 3 MOVE-FA trial is an 18-month parallel arm, placebo-controlled study evaluating vatiquinone versus placebo in approximately 110 children and young adults with FA. The primary endpoint is the change from baseline in the modified Friedreich ataxia rating scale (mFARS), with key secondary endpoints assessing ambulation and activities of daily living. This endpoint strategy was developed in consultation with both the FDA and European Medicines Agency. The study will include sites in the U.S., E.U., Australia and Latin America.

“FARA and the FA community are grateful to PTC Therapeutics for their commitment to advancing treatments for Friedreich ataxia,” stated Jennifer Farmer, Chief Executive Officer, FARA. “We are excited for the PTC743 program to reach this milestone of opening enrollment of the MOVE-FA clinical trial and we look forward to assisting PTC with recruitment in the US and internationally.”

About Vatiquinone (PTC743)
Vatiquinone is an investigational small molecule that inhibits 15-Lipoxygenase, an enzyme that is a key regulator of the oxidative stress and inflammation response pathways that underpin neurological disease pathology. Vatiquinone has been evaluated in a number of clinical studies in which it has been demonstrated to have an impact on mortality risk and a number of neurological and neuromuscular disease symptoms. In more than 500 patients with duration of exposure up to 10 years, vatiquinone has demonstrated a favorable safety profile.

About PTC Therapeutics, Inc.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.

For More Information:
Media:

Jane Baj

+1 (908) 912-9167
[email protected] 

Investors:

Lisa Hayes

+1 (732) 354 8687
[email protected] 

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data and other matters; PTC’s strategy, future operations, future financial position, future revenues and projected costs; and the objectives of management. Other forward-looking statements may be identified by the words “guidance,” “plan,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions.

PTC’s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC’s products or product candidates that PTC commercializes or may commercialize in the future; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC’s products and product candidates; PTC’s scientific approach and general development progress; and the factors discussed in the “Risk Factors” section of PTC’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC’s other filings with the SEC. You are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory or prove to be commercially successful.

The forward-looking statements contained herein represent PTC’s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

¹ National Organization for Rare Disorders (NORD) (2020). Friedreich’s Ataxia. https://rarediseases.org/rare-diseases/friedreichs-ataxia/. Accessed November 13, 2020. 

View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-announces-initiation-of-global-phase-3-clinical-trial-to-evaluate-vatiquinone-in-friedreich-ataxia-301181396.html

SOURCE PTC Therapeutics, Inc.